The activation of HIF-1 by hypoxia and/or high levels of ROS triggers the transcription of hypoxia-responsive genes that have been associated with a genetic and epigenetic adaptation of tumor cells promoting tumor progression events and also PDT therapeutic resistance [3,25]. Here, HIF1A is linked to neoplasm.